Novartis licenses Genentech's AMD candidate Lucentis
Novartis Ophthalmics AG licensed exclusive worldwide rights outside of N. America to Genentech's Lucentis (ranibizumab), a drug candidate in US Phase III trials for treating the wet form of age-related macular degeneration (AMD).
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.